FindTrial
Sign In

A Phase 2/3, multicenter, randomized, investigator-blinded study to evaluate the efficacy and safety of NK-104 versus Atorvastatin in Chinese patients with hypercholesterolaemia

A Phase 2/3, multicenter, randomized, investigator-blinded study to evaluate the efficacy and safety of NK-104 versus Atorvastatin in Chinese patients with hypercholesterolaemia

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220211
Enrollment
Unknown
Registered
2006-02-16
Start date
2006-02-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypercholesterolaemia

Interventions

investigational material(s) Generic name etc : NK-104 INN of investigational material : Therapeutic category code : 218 Agents for hyperlipidemias Dosage and Administration for Investigational materi

Sponsors

Kowa Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Main Inclusion Criteria: Male or female patients diagnosed with hypercholesterolaemia Main Exclusion Criteria: Patients with homozygous familial hypercholesterolaemia

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy, Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026